A study testing whether a new weekly shot, tirzepatide, can help people reduce liver fat.

Recruiting now. Registry record last updated August 12, 2026.

Who can join: Adults 21 to 100, have metabolic alcohol-associated liver disease, BMI 25+.
What you take: tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 13 months.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor National Institute on Alcohol Abuse and Alcoholism (NIAAA)Drug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 120

What this study is for

Primary condition: Metabolic Alcohol-associated Liver Disease. Also studied in: Alcohol Use Disorder.

Full scientific study title: Tirzepatide in MetALD.

Who can join

Age21 to 100SexAnyBMI25 to 40

Adults 21 to 100, have metabolic alcohol-associated liver disease, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age 21 or older
Ability to provide written informed consent
Females: Negative urine pregnancy test, not currently breastfeeding, agree to abstain or use accepted form of contraception including use of oral contraceptives and an additional barrier method of contraceptive such as condoms; use of an approved IUD or other longacting reversible contraceptive (LARC); have a male sexual partner who is surgically sterilized; or have exclusively female sexual partner(s)
Males: Agree to abstain or use accepted form of contraception, such as condoms.
Diagnosis of AUD as confirmed by MINI

Key exclusion criteria

Treatment seeking for alcohol use disorder
History of a serious hypersensitivity reaction to GLP-1RA/GIPRA
Current/past use of GLP-1RA/GIPRA within the last 3 months
Clinically significant and/or unstable cardiovascular disease over the past 12 months
History of diabetes mellitus or blood hemoglobin A1c (HbA1c) \>= 6.5 % at screening

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Maryland1 site

National Institutes of Health Clinical Center
Bethesda, Maryland
NIH Clinical Center Office of Patient Recruitment (OPR)800-411-1222ccopr@nih.gov

Follow this trial

We email you if NCT07046819 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: June 11, 2026. Expected completion: July 30, 2027. Last updated on ClinicalTrials.gov: August 12, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.